Alzheon Appoints Laivins as Head of Commercial Strategy and Planning

FRAMINGHAM – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced today, January 7, Peter N. Laivins, MBA, has been appointed Head of Commercial Strategy and Planning.

Laivins brings more than 20 years of leadership in the biopharmaceutical industry, with broad expertise in business strategy and commercialization for Alzheimer’s therapies, including his experience at Pfizer launching ARICEPT® for symptomatic treatment for Alzheimer’s disease and at Elan Biopharmaceuticals leading commercial strategy for bapineuzumab as anti-amyloid immunotherapy for Alzheimer’s disease.

“Peter brings unparalleled depth of business and commercial expertise to Alzheon, with a unique track record of shaping the Alzheimer’s commercial landscape and a career-long passion to fight this debilitating disease,” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon. “Peter’s skills will be invaluable as we move our lead drug ALZ-801 into Phase 3 trials and prepare for future commercialization of potentially the first oral and well tolerated disease-modifying treatment for millions of Alzheimer’s patients and their families.”

Most recently, Laivins was the Senior Vice President of Strategic Development Program Leadership at Tesaro, Inc., with oversight of five development teams, portfolio management and competitive intelligence.

Previously, at Merrimack Pharmaceuticals, he served as Senior Vice President and Head of Late Stage Development, where he led the successful clinical development, NDA submission and FDA approval of Onyvide® – the first new therapy for pancreatic cancer in two decades.

Laivins’ career in neuroscience drug development includes his role as Vice President of Strategic Brand Management for Elan Biopharmaceuticals, with responsibility for the Alzheimer’s portfolio, including bapineuzumab, and the multiple sclerosis portfolio, including TYSABRI®.

At Pfizer, Laivins held positions of increasing responsibility, including the Global Team Leader in Neuroscience, leading the launch of Aricept® – which achieved peak sales exceeding $3 billion.

Beyond neuroscience, he also served as Group Leader for US Oncology Marketing at Pfizer.

Laivins is a graduate of McGill University with a Bachelor of Science in microbiology and immunology and Master of Business Administration.

“I’m excited to join the team at Alzheon at this important juncture in Alzheimer’s drug development. Last year we saw convincing clinical validation of anti-amyloid therapy, which confirmed that targeting amyloid toxicity can slow disease progression and provide clinical improvement in patients,” said Laivins. “We believe ALZ-801 could be transformative as the first oral disease modifying treatment for Alzheimer’s and provide an important advance for patients and their families.”

Alzheon’s lead product candidate, ALZ-801, an oral anti-amyloid drug candidate that is an optimized prodrug of tramiprosate, has shown promising results in analyses of clinical data1,2 and a novel therapeutic mechanism of action.3 ALZ-801 has received Fast Track designation from the U.S. Food and Drug Administration.

Alzheon, Inc. has its headquarters in Framingham.

Framingham Source Editor Susan Petroni

Susan Petroni Framingham Source Editor Email: Phone: 508-315-7176

Leave a Reply